Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 3

2(33.3%)

Phase 1

2(33.3%)

6Total

Phase 2(2)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03291470Phase 3Completed

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Role: lead

NCT03203330Phase 3Active Not Recruiting

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Role: lead

NCT05276011Phase 2Not Yet Recruiting

A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis

Role: lead

NCT06144970Phase 1Not Yet Recruiting

Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease

Role: lead

NCT00599248Phase 1Completed

Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee

Role: lead

NCT01221441Phase 2Completed

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

Role: lead

All 6 trials loaded